GE HealthCare Reports the US FDA’s Approval of Flyrcado (Flurpiridaz F 18) PET Radiotracer for Improved CAD Diagnosis 

Shots:    

• The US FDA has approved Flyrcado injection as a PET MPI agent to diagnose CAD, with its launch planned in early 2025  

• The effectiveness of Flyrcado  was assessed under the P-III (AURORA) study in comparison with both invasive coronary angiography as a standard and SPECT MPI to identify CAD   

• In addition, GE HealthCare secured exclusive global commercialization rights of the flurpiridaz F 18 from Lantheus in 2017, funding its development until approval. Lantheus will partner on commercialization through a joint steering committee & is entitled to get royalties based on sales milestones 

Ref: GE HealthCare | Image: GE HealthCare| Press Release

Related News:- BMS’ Cobenfy (Xanomeline and Trospium Chloride) Receives the US FDA Approval for Treating Schizophrenia 

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com